Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Baird Cuts Price Target on Enanta Pharma (ENTA) Despite Bottom-Line Beat
February 9, 2016 7:28 AM ESTBaird remains Neutral on Enanta Pharmaceuticals (NASDAQ: ENTA), and cut the price target to $22.00 (from $36.00), following the company's 1Q. Non-GAAP EPS was reported at $1.36, beating consensus estimates of $1.13. The company ended the quarter with $236.6M in cash, which management expects will last for the... More
Enanta Pharma (ENTA) Tops Q1 EPS by 23c
February 8, 2016 4:05 PM ESTEnanta Pharma (NASDAQ: ENTA) reported Q1 EPS of $1.36, $0.23 better than the analyst estimate of $1.13. Revenue for the quarter came in at $48.4 million versus the consensus estimate of $47.05 million.
For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.
... More